Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

Saint Francis treated its first patient with pulsed-field ablation, which delivers pulsed electric fields to tissue to treat ...

One of the most commonly used types of medication to prevent strokes is blood thinners. These medications reduce the risk of ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it. Whenever he’d overexert himself, he’d feel “different,” but it would go away with rest.

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

less invasive treatment option. The Medtronic PulseSelect™ Pulsed Field Ablation System uses pulsed electric fields to target and eliminate the muscle cells that cause AFib. This innovative ...

Medtronic (NYSE: MDT) today reported study results highlighting AFib detection with its Linq family of insertable cardiac monitors (ICM).